Search

Displaying results 3211 - 3220 of 10000 in total
  1. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative … CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.

  2. Drug

    Cabergoline

    go.drugbank.com/drugs/DB00248
    ApprovedInvestigational

    Cabergoline possesses potent agonist activity on dopamine D2 receptors. … Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome.

    Synonyms: (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
  3. Drug

    Phenylbutyric acid

    go.drugbank.com/drugs/DB06819
    ApprovedInvestigational

    Phenylbutyric acid is a fatty acid and a derivative of butyric acid naturally produced by colonic bacteria fermentation. It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical...

    Synonyms: 4-Phenyl-n-butyric acid, γ-Phenyl-n-butyric acid
  4. Drug

    Reboxetine

    go.drugbank.com/drugs/DB00234
    ApprovedInvestigationalWithdrawn

    Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD.

  5. Drug

    Verteporfin

    go.drugbank.com/drugs/DB00460
    ApprovedInvestigational

    It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. … Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet

  6. Drug

    Hydroxyamphetamine

    go.drugbank.com/drugs/DB09352
    Approved

    stinging in the eyes. … Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and temporary

  7. Drug

    Xenon Xe-129

    go.drugbank.com/drugs/DB17386
    ApprovedInvestigational

    Hyperpolarized Xenon-129 (Xe-129) is a contrast agent used in the lung's clinical magnetic resonance imaging (MRI). … [A255183] In December 2022, the FDA approved the use of hyperpolarized Xe-129 for use with MRI for the evaluation of lung ventilation.

  8. Drug

    Iofetamine I-123

    go.drugbank.com/drugs/DB09480
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Bifidobacterium longum infantis

    go.drugbank.com/drugs/DB14222
    ApprovedInvestigationalWithdrawn

    Mixtures: BİOBER-ZN ORAL SÜSPANSİYON İÇEREN FLAKON, 5 ADET
  10. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved